Prospective study on the incidence of XXXX and @entity7890 in Europe.

@entity1 @entity154 @entity3930 @entity1494 @entity13393 @entity7891 @entity7890
OBJECTIVE: On behalf of the European Society of Paediatric Urology (ESPU), a prospective study was designed with the aim of defining the actual number of babies born with @entity1494 , @entity7891 , and @entity7890 in Europe over a 12-month period, and verifying the distribution of the @entity7891 @entity1 born during the study period among the different paediatric urology centres in Europe. STUDY DESIGN: The study was structured with a chief investigator and one national investigator for each country enrolled in the study. The national investigators nominated one local investigator for each European centre of paediatric surgery/paediatric urology and urology where the @entity7891 complex could potentially be treated. The local investigators were responsible for reporting babies treated in their institutions for @entity1494 and/or @entity7890 . During 2010, every 3 months, an electronic survey (Figure) was e-mailed to the local investigators asking them to report babies treated or referred for treatment during the previous 3 months. RESULTS: One-hundred and sixteen centres in 27 European counties were enrolled in the study. The overall response rate for the four online surveys was 79%. Two-hundred and thirty-eight babies were reported to be born with a condition within the bladder @entity13393 complex (BEEC): 71 primary @entity7890 (66 males), 146 classic @entity1494 (97 males) of which two were female @entity1494 variant, and 21 @entity7891 (17 males). Two of 67 (3%) @entity3930 , 24/146 (16.4%) @entity1494 , and 6/21 (28%) @entity7891 were antenatally diagnosed. @entity154 were reported in 2/71 (2.8%) @entity7890 @entity1 , 8/146 (5.5%) @entity1494 @entity1 , and 15/21 (71.4%) @entity7891 @entity1 . One-hundred and forty-seven (62%) of the 238 babies born in Europe with a condition within the @entity7891 spectrum during 2010 were transferred from other institutions for treatment (36 @entity3930 , 97 @entity1494 , and 14 @entity7891 ). Only 12 centres treated six or more @entity7891 and or @entity7890 @entity1 during the study period; 52 treated between one and five @entity1 , of which 22 treated only one case in 12 months. DISCUSSION: This study provides a contemporary incidence of the BEEC in Europe. It demonstrates also that only a minority (19%) of the European centres involved in the treatment of @entity7891 can be considered "high volume" @entity7891 centres. CONCLUSION: There is a case for proposing a rationalisation of the treatment of this group of conditions in a small number of @entity7891 units around Europe.
